
Opinion|Videos|June 23, 2025
Lymph Node–Positive Kidney Disease: Future Implications of PET Imaging
Panelists discuss how the new PET technology could identify lymph node involvement not visible on conventional imaging, providing actionable information for surgical planning or indicating the need for systemic therapy rather than surgery alone.
Advertisement
Episodes in this series

Lymph Node Management and Molecular Imaging
Main Discussion Topics:
- The current approach typically limits lymph node dissection to radiographically evident disease.
- Molecular imaging could identify nodal disease missed by conventional imaging.
- Detection of nodal disease by molecular imaging would be actionable.
- Could influence surgical planning or shift patients toward systemic therapy approaches
Key Points for Physicians:
- Neither expert routinely performs lymph node dissection without radiographic indication.
- A positive node on molecular imaging would likely change management.
- Options include targeted lymph node dissection or initiation of systemic therapy.
- Improved node detection could help homogenize treatment groups in clinical trials.
Notable Insights:
Nodal disease detected by molecular imaging is considered biologically significant and likely indicates systemic disease requiring more than surgery alone.
Clinical Significance:
Molecular imaging could fundamentally change nodal staging and management decisions, potentially moving patients from surgery-first approaches to systemic therapy.
Advertisement
Related to this article

Interim phase 3 data show a 58% reduction in the risk of metastasis or death with the addition of darolutamide to ADT + radiation.

Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.

Perioperative durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin-ejfv (Padcev) cut the risk of EFS events by 49% and death by 42% in cisplatin-ineligible MIBC.

The PROTEUS substudy addresses a key limitation of the main study, which had no surgery-alone control arm.

At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.

The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.

Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Advertisement
Advertisement
Trending on Urology Times
1
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
2
VOLGA: Durvalumab plus enfortumab vedotin improves EFS, OS in MIBC
3
In situ immunotherapy shows encouraging survival findings in prostate cancer
4
Adding darolutamide to ADT and radiation improves MFS in very high-risk localized prostate cancer
5

